Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023, led to a surge in demand for compounded versions of the drugs.

GET 6 MONTHS FREEIn a follow-up TikTok post on March 31, O'Donnell gave another shoutout to Mounjaro for its impact on her weight loss while reflecting on the financial limitations of the drug's ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...